Y. Tanaka, S. Kubo, H. Yamanaka, K. Amano, S. Hirata et al., Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(Ò) as Biological Intensive Treatment for RA (ORBIT) study, Mod. Rheumatol, vol.24, pp.754-762, 2014.

V. Viglietta, K. Bourcier, G. J. Buckle, B. Healy, H. L. Weiner et al., CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial, Neurology, vol.71, pp.917-924, 2008.

, Clinical Trials database. Available, 2014.

T. T. Chang, C. Jabs, R. A. Sobel, V. K. Kuchroo, and A. H. Sharpe, Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis, J. Exp. Med, vol.190, pp.733-740, 1999.

T. Chitnis, N. Najafian, K. A. Abdallah, V. Dong, H. Yagita et al., CD28-independent induction of experimental autoimmune encephalomyelitis, J. Clin. Invest, vol.107, pp.575-583, 2001.

A. J. Oliveira-dos-santos, A. Ho, Y. Tada, J. J. Lafaille, S. Tonegawa et al., CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis, J. Immunol, vol.162, pp.4490-4495, 1999.

S. J. Khoury, E. Akalin, A. Chandraker, L. A. Turka, P. S. Linsley et al., CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system, J. Immunol, vol.155, pp.4521-4524, 1995.

P. J. Perrin, C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke, Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis, J. Immunol, vol.163, pp.1704-1710, 1999.

N. Poirier, G. Blancho, and B. Vanhove, CD28-specific immunomodulating antibodies: what can be learned from experimental models?, Am. J. Transplant, vol.12, pp.1682-1690, 2012.

G. Suntharalingam, M. R. Perry, S. Ward, S. J. Brett, A. Castello-cortes et al., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N. Engl. J. Med, vol.355, pp.1018-1028, 2006.

N. Poirier, C. Mary, N. Dilek, J. Hervouet, D. Minault et al., Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab9 antibody, Am. J. Transplant, vol.12, pp.2630-2640, 2012.

N. Poirier, C. Mary, S. L. Bas-bernardet, V. Daguin, L. Belarif et al., Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28, MAbs, vol.6, pp.697-707, 2014.

B. A. 't-hart and L. Massacesi, Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus), J. Neuropathol. Exp. Neurol, vol.68, pp.341-355, 2009.

N. Kerlero-de-rosbo, H. P. Brok, J. Bauer, J. F. Kaye, B. A. Hart et al., Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T-and B-cell epitopes, J. Neuroimmunol, vol.110, pp.83-96, 2000.

K. G. Haanstra, S. O. Hofman, D. M. Lopes-estêvão, E. L. Blezer, J. Bauer et al., Antagonizing the a 4 b 1 integrin, but not a 4 b 7 , inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis, J. Immunol, vol.190, pp.1961-1973, 2013.

B. A. Hart, J. Bauer, H. P. Brok, and S. Amor, Non-human primate models of experimental autoimmune encephalomyelitis: variations on a theme, J. Neuroimmunol, vol.168, pp.1-12, 2005.

A. Bellizzi, C. Nardis, E. Anzivino, D. Rodìo, D. Fioriti et al., Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies, J. Neurovirol, vol.18, pp.1-11, 2012.

M. Green and M. G. Michaels, Epstein-Barr virus infection and posttransplant lymphoproliferative disorder, Am. J. Transplant, vol.13, pp.41-54, 2013.

H. Nakajima, A. Takayama, T. Ito, and T. Yoshikawa, Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy, BMJ Case Rep, p.2013009731, 2013.

F. L?-uhder, Y. Huang, K. M. Dennehy, C. Guntermann, I. Uller et al., Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists, J. Exp. Med, vol.197, pp.955-966, 2003.

K. G. Haanstra, M. J. Van-der-maas, B. A. Hart, and M. Jonker, Characterization of naturally occurring CD4 + CD25 + regulatory T cells in rhesus monkeys, Transplantation, vol.85, pp.1185-1192, 2008.

K. G. Haanstra, S. A. Jagessar, A. L. Bauchet, M. Doussau, C. M. Fovet et al., Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species, J. Neuroimmune Pharmacol, vol.8, pp.1251-1264, 2013.

, Quesgen Systems, Inc. Data management for clinical research, 2014.

N. Kerlero-de-rosbo, M. Hoffman, I. Mendel, I. Yust, J. Kaye et al., Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions, Eur. J. Immunol, vol.27, pp.3059-3069, 1997.

H. P. Brok, L. Boven, M. Van-meurs, N. Kerlero-de-rosbo, L. Celebi-paul et al., The human CMV-UL86 peptide 981-1003 shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 34-56, but lacks the capacity to induce EAE in rhesus monkeys, J. Neuroimmunol, vol.182, pp.135-152, 2007.

H. P. Brok, J. Bauer, M. Jonker, E. Blezer, S. Amor et al., Non-human primate models of multiple sclerosis, Immunol. Rev, vol.183, pp.173-185, 2001.

S. A. Jagessar, P. A. Smith, E. Blezer, C. Delarasse, D. Pham-dinh et al., Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets, J. Neuropathol. Exp. Neurol, vol.67, pp.326-340, 2008.

, World Health Organization Hepatitis E virus standard for RNA assay, 2014.

P. Cantalupo, A. Doering, C. S. Sullivan, A. Pal, K. W. Peden et al., Complete nucleotide sequence of polyomavirus SA12, J. Virol, vol.79, pp.13094-13104, 2005.

N. Dilek, N. Poirier, P. Hulin, F. Coulon, C. Mary et al., Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells, PLoS One, vol.8, p.83139, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02165637

N. Poirier, A. M. Azimzadeh, T. Zhang, N. Dilek, C. Mary et al., Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation, Sci. Transl. Med, vol.2, pp.17-27, 2010.

S. A. Jagessar, N. Heijmans, E. L. Blezer, J. Bauer, J. H. Blokhuis et al., Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant, Eur. J. Immunol, vol.42, pp.217-227, 2012.

A. M. Girvin, M. C. Canto, L. Rhee, B. Salomon, A. Sharpe et al., A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade, J. Immunol, vol.164, pp.136-143, 2000.

B. A. 't-hart, B. Gran, and R. Weissert, EAE: imperfect but useful models of multiple sclerosis, Trends Mol. Med, vol.17, pp.119-125, 2011.

A. B. Adams, M. A. Williams, T. R. Jones, N. Shirasugi, M. M. Durham et al., Heterologous immunity provides a potent barrier to transplantation tolerance, J. Clin. Invest, vol.111, pp.1887-1895, 2003.

M. A. Williams, T. M. Onami, A. B. Adams, M. M. Durham, T. C. Pearson et al., Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen, J. Immunol, vol.169, pp.5387-5391, 2002.

B. A. 't-hart, S. A. Jagessar, K. Haanstra, E. Verschoor, J. D. Laman et al., The primate EAE model points at EBV-infected B cells as a preferential therapy target in multiple sclerosis, Front. Immunol, vol.4, p.145, 2013.

J. M. Lumsden, J. A. Williams, and R. J. Hodes, Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo, J. Immunol, vol.170, pp.781-787, 2003.

F. C. Rau, J. Dieter, Z. Luo, S. O. Priest, and N. Baumgarth, B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion, J. Immunol, vol.183, pp.7661-7671, 2009.

M. Scarsi, L. Paolini, D. Ricotta, A. Pedrini, S. Piantoni et al., Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis, J. Rheumatol, vol.41, pp.666-672, 2014.

R. Van-lambalgen and M. Jonker, Experimental allergic encephalomyelitis in rhesus monkeys: I. Immunological parameters in EAE resistant and susceptible rhesus monkeys, Clin. Exp. Immunol, vol.68, pp.100-107, 1987.

B. Aubé, S. A. Lévesque, A. Paré, É. Chamma, H. Kébir et al., Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases, J. Immunol, vol.193, pp.2438-2454, 2014.

J. S. Stoolman, P. C. Duncker, A. K. Huber, and B. M. Segal, Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis, J. Immunol, vol.193, pp.564-570, 2014.

S. B. Simmons, D. Liggitt, and J. M. Goverman, Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis, J. Immunol, vol.193, pp.555-563, 2014.

R. C. Dale, C. Sousa, W. K. Chong, T. C. Cox, B. Harding et al., Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children, Brain, vol.123, pp.2407-2422, 2000.

S. Schwarz, A. Mohr, M. Knauth, B. Wildemann, and B. Storch-hagenlocher, Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients, Neurology, vol.56, pp.1313-1318, 2001.

D. Franciotta, E. Zardini, S. Ravaglia, G. Piccolo, L. Andreoni et al., Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis, J. Neurol. Sci, vol.247, pp.202-207, 2006.

T. Ishizu, M. Minohara, T. Ichiyama, R. Kira, M. Tanaka et al., CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis, J. Neuroimmunol, vol.175, pp.52-58, 2006.

T. Maki, A. Carville, I. E. Stillman, K. Sato, T. Kodaka et al., SV40 infection associated with rituximab treatment after kidney transplantation in nonhuman primates, Transplantation, vol.85, pp.893-902, 2008.

M. A. Simon, Polyomaviruses of nonhuman primates: implications for research, Comp. Med, vol.58, pp.51-56, 2008.

J. H. Simmons, Herpesvirus infections of laboratory macaques, J. Immunotoxicol, vol.7, pp.102-113, 2010.

M. L. Gulley and W. Tang, Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder, Clin. Microbiol. Rev, vol.23, pp.350-366, 2010.